Another study comparing patients with history of proliferative lesions with atypia with matched screenings based on age, density, and breast cancer family history also found no differences in mammographic sensitivity or proportion of interval cancers; however, they also reported lower specificity in the atypical proliferative lesions group [19]. MRI Breast Without IV Contrast There is no relevant literature to support the use of MRI breast without IV contrast for screening in this clinical scenario. Sestamibi MBI There is no relevant literature to support the use of Tc-99m sestamibi molecular breast imaging (MBI) in this clinical scenario. Variant 2: Female. Age 30 to 39 years. Postsurgical excision with nonmalignant pathology. Asymptomatic. Initial imaging. Benign breast disease can be classified into 3 broad categories: nonproliferative lesions, proliferative lesions without atypia, and proliferative lesions with atypia. Nonproliferative lesions include benign calcifications, fibrocystic changes, fibroadenomas, lipomas, fat necrosis, and nonsclerosing adenosis. Proliferative lesions without atypia include usual ductal hyperplasia, sclerosing adenosis, complex fibroadenomas, radial scars/complex sclerosing lesions, papillomas, and papillomatosis. Proliferative lesions with atypia include atypical ductal hyperplasia, atypical lobular hyperplasia, LCIS, and flat epithelial atypia [4,5]. Benign breast disease and breast tissue density are independent risk factors for developing breast cancer [5,6]. One study of women from the BCSC reported breast cancer in 25% of women with excision for proliferative lesions with atypia [7]. Almost 30% of women with breast cancer have a history of benign breast disease [4]. Imaging after Breast Surgery FDG-PET Breast Dedicated There is no relevant literature to support the use of FDG-PET breast in this clinical scenario.
Imaging after Breast Surgery. Another study comparing patients with history of proliferative lesions with atypia with matched screenings based on age, density, and breast cancer family history also found no differences in mammographic sensitivity or proportion of interval cancers; however, they also reported lower specificity in the atypical proliferative lesions group [19]. MRI Breast Without IV Contrast There is no relevant literature to support the use of MRI breast without IV contrast for screening in this clinical scenario. Sestamibi MBI There is no relevant literature to support the use of Tc-99m sestamibi molecular breast imaging (MBI) in this clinical scenario. Variant 2: Female. Age 30 to 39 years. Postsurgical excision with nonmalignant pathology. Asymptomatic. Initial imaging. Benign breast disease can be classified into 3 broad categories: nonproliferative lesions, proliferative lesions without atypia, and proliferative lesions with atypia. Nonproliferative lesions include benign calcifications, fibrocystic changes, fibroadenomas, lipomas, fat necrosis, and nonsclerosing adenosis. Proliferative lesions without atypia include usual ductal hyperplasia, sclerosing adenosis, complex fibroadenomas, radial scars/complex sclerosing lesions, papillomas, and papillomatosis. Proliferative lesions with atypia include atypical ductal hyperplasia, atypical lobular hyperplasia, LCIS, and flat epithelial atypia [4,5]. Benign breast disease and breast tissue density are independent risk factors for developing breast cancer [5,6]. One study of women from the BCSC reported breast cancer in 25% of women with excision for proliferative lesions with atypia [7]. Almost 30% of women with breast cancer have a history of benign breast disease [4]. Imaging after Breast Surgery FDG-PET Breast Dedicated There is no relevant literature to support the use of FDG-PET breast in this clinical scenario.